Shire Fosrenol "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire's non-calcium phosphate binding agent Fosrenol (lanthanum carbonate) is "approvable" Feb. 28 for treatment of end-stage renal disease patients undergoing hemodialysis. FDA is asking for additional data and analysis to address "a number of remaining questions," firm says. The agency previously requested a study examining long-term efficacy in bone histology (Pharmaceutical Approvals Monthly, Feb. 1, p. 3). Shire continues to forecast a U.S. launch prior to the end of 200
You may also be interested in...
Shire Recruiting 80-90 Fosrenol Reps; Adderall XR Adult User Fee Is Mid-Year
Shire is recruiting 80 to 90 Fosrenol sales reps in anticipation of a second-half 2004 launch of the non-calcium phosphate binder for treatment of end-stage renal disease, the firm said April 29.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.